End-of-treatment VALOR-HCM analyses reassure on use in women, suggest disease-modifying potential
Phase 3 ODYSSEY-HCM trial of mavacamten leaves lingering questions about potential broader use
An abundance of promising studies are on the horizon
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement